Proniras

Proniras is a private, clinical-stage biotech targeting the significant unmet need in opioid use disorder (OUD) treatment with its lead candidate, tezampanel (PRN-001-01). The company's approach modulates glutaminergic signaling to address withdrawal and addiction, a novel mechanism that avoids opioid receptor interaction. With a seasoned leadership team and recent Series B financing, Proniras is positioned to advance tezampanel through Phase 1 clinical trials. Its strategy is supported by non-dilutive funding from grants like those from the National Institute on Drug Abuse (NIDA).

Novel small-molecule modulators of glutaminergic signaling, specifically targeting AMPA and kainate receptors to treat addiction and CNS disorders without direct opioid system interaction.

Competition includes approved opioid-based therapies (methadone, buprenorphine) and emerging non-opioid approaches. Tezampanel's differentiation lies in its unique AMPA/kainate antagonism mechanism, aiming to treat withdrawal and addiction directly at the neural circuit level without opioid receptor engagement, potentially offering a new class of treatment.